Matthew William Burnell Trotter,Patrick Hagner,Courtney G. Havens,Rajesh Chopra,Anita Gandhi,Anke Klippel,Maria Yinglin Wang,Mike Breider,Suzana Sturlini Couto,Yan Ren,Paul Hollenbach,Kyle MacBeth
申请号：
US15101869
公开号：
US20160313300A1
申请日:
2014.12.05
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
